Biomarkers for Parkinsonian Syndromes NCT06501469
ClinicalTrials.gov Identifier: [NCT06501469](https://clinicaltrials.gov/study/NCT06501469)
Overview
Mermaid diagram (expand to render)
Biomarkers in Parkinsonian Syndromes (NCT06501469) is a prospective observational study designed to identify and validate biomarkers for parkinsonian syndromes, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS)[@clinicaltrialsgov2026]. This study addresses a critical unmet need in neurodegenerative disease research: the lack of reliable biomarker-based diagnostic tools that can distinguish between these overlapping syndromes at early disease stages.
| Field | Value |
|-----------|-----------|
| NCT Number | NCT06501469 |
| Status | Recruiting |
| Study Type | Prospective Observational Cohort |
| Follow-up Duration | At least 5 years |
| Primary Outcome | Establishment of clinical diagnosis |
| Secondary Outcomes | Biomarker validation, disease progression tracking |
| Enrollment Target | 500-1000 participants |
| Age Range | 40-85 years |
| Study Sites | Multiple academic medical centers |
Scientific Rationale
The Diagnostic Challenge
Early accurate diagnosis of parkinsonian syndromes remains a significant challenge in neurology. While clinical criteria exist for PSP, MSA, and CBS, diagnostic accuracy in early disease stages is limited to approximately 50-70%[@2024_ninds_psp_criteria]. The key challenges include:
Phenotypic Overlap: PSP, MSA, and CBS share common features including parkinsonism, akinesia, rigidity, and postural instability
Atypical Presentations: Early-stage patients often present with incomplete or atypical symptom patterns
Variable Progression: Disease progression rates differ significantly between and within syndromes
No Definitive Biomarkers: Currently, no validated biomarkers exist for definitive antemortem diagnosisThis study aims to address these gaps by systematically collecting:
- Imaging biomarkers (MRI, PET, SPECT)
- Wet biomarkers (blood, CSF)
- Clinical data and longitudinal assessments
- Digital biomarkers (wearable sensor data)
Disease Background
Progressive Supranuclear Palsy
PSP is a 4R-tauopathy characterized by accumulation of abnormal tau protein in the basal ganglia, brainstem, and cerebellar structures. The classic Richardson's phenotype presents with vertical supranuclear gaze palsy, early falls, and frontal cognitive impairment. However, multiple variants are recognized:
- PSP-Parkinsonism (PSP-P): Predominant parkinsonian features, slower progression
- PSP-Pure Akinesia with Gait Freezing (PAGF): Early gait freezing, minimal ocular findings
- PSP-Cerebellar (PSP-C): Prominent cerebellar ataxia
- Frontal Variant PSP: Predominant behavioral and cognitive symptoms
Multiple System Atrophy
MSA is a synucleinopathy divided into two subtypes:
- MSA-P: Predominant parkinsonian features with autonomic failure
- MSA-C: Predominant cerebellar ataxia with autonomic failure
Key pathological features include glial cytoplasmic inclusions (GCIs) containing alpha-synuclein in oligodendrocytes.
Corticobasal Syndrome
CBS is a clinically heterogeneous syndrome typically characterized by:
- Asymmetric parkinsonism
- Cortical sensory loss
- Alien limb phenomena
- Apraxia
- Cognitive decline
Pathologically, CBS can be due to CBD (corticobasal degeneration, a 4R-tauopathy), AD, or PSP pathology.
Study Design
Inclusion Criteria
The study recruits patients with parkinsonian syndromes at early disease stages who will be followed prospectively until a definitive clinical diagnosis is established. Key eligibility includes:
- Age 40-85 years
- Clinical diagnosis or suspicion of PSP, MSA, or CBS
- Disease duration <5 years
- Ability to undergo repeated MRI and biomarker collection
- Informed consent
Data Collection Timeline
| Visit | Timepoint | Assessments |
|-----------|---------------|-----------------|
| Baseline | Day 0 | Full biomarker panel, clinical assessments |
| Year 1 | 12 months | Repeat biomarker panel, clinical scores |
| Year 2 | 24 months | Repeat biomarker panel, clinical scores |
| Year 3 | 36 months | Repeat biomarker panel, clinical scores |
| Year 5 | 60 months | Final assessment, definitive diagnosis |
Biomarker Types Collected
| Biomarker Type | Examples | Clinical Utility |
|-------------------|--------------|---------------------|
| Neuroimaging | MRI, PET, SPECT | Structural/functional changes |
| Fluid biomarkers | CSF, blood, serum | Protein signatures, neurodegeneration markers |
| Clinical scales | Motor assessments, cognitive tests | Phenotypic characterization |
| Digital biomarkers | Wearable sensor data | Real-world function monitoring |
Neuroimaging Biomarkers
Magnetic Resonance Imaging (MRI)
Structural MRI Markers
MRI plays a crucial role in differentiating parkinsonian syndromes through characteristic atrophy patterns:
PSP Imaging hallmarks:
- Midbrain atrophy: "Hummingbird sign" on midsagittal MRI
- Superior cerebellar peduncle (SCP) atrophy: Contributing to the "Mickey Mouse sign"
- Frontal lobe atrophy: Particularly in dorsal prefrontal regions
- Third ventricle enlargement: Reflecting thalamic and hypothalamic involvement
- Pontine tegmental atrophy
MSA imaging hallmarks:
- Hot cross bun sign: Pontine crossing fiber degeneration on T2-weighted MRI
- Cerebellar atrophy: Especially in the vermis for MSA-C
- Putaminal atrophy and hypointensity: With peripheral rim hyperintensity
- Brainstem atrophy: Less pronounced than in PSP
CBS imaging hallmarks:
- Asymmetric cortical atrophy: Parietal and frontal regions
- Central atrophy: Including the substantia nigra and red nucleus
- Corpus callosum thinning: Particularly in the body region
Advanced MRI Techniques
- Diffusion Tensor Imaging (DTI): Measures white matter integrity, showing distinct patterns of fractional anisotropy reduction
- Susceptibility-Weighted Imaging (SWI): Detects iron deposition in basal ganglia
- Quantitative Susceptibility Mapping (QSM): Quantifies iron accumulation
- Magnetization Transfer Imaging: Sensitive to myelin changes
Positron Emission Tomography (PET)
Tau PET Imaging
Tau PET tracers have shown differential binding patterns across parkinsonian syndromes:
- PI-2620: High affinity for 3R/4R tau, shows elevated binding in PSP basal ganglia
- PM-PBB3: Binds to both 3R/4R tau and 2N tau isoforms
- FTP (Flortaucipir): Originally developed for AD tau, shows binding in PSP
The pattern of tau PET signal can help differentiate[@tau_pet_psp]:
- PSP: Elevated binding in basal ganglia, midbrain, dentate nucleus
- MSA: Generally lower tau binding, more focal patterns
- CBS: Variable patterns depending on underlying pathology
Amyloid PET
- Florbetapir (18F-AV-45): Rules in/out AD pathology
- Helps determine whether CBS cases have co-occurring AD pathology
Dopaminergic Imaging
- DAT SPECT/PET: Measures dopamine transporter availability
- Reduced uptake in both PSP and MSA
- More severe reduction in MSA compared to PSP
- Helps differentiate from essential tremor and psychogenic parkinsonism
- FP-CIT (DaTscan): FDA-approved for differentiating degenerative parkinsonism
- Characteristic hypometabolism patterns:
- PSP: Midline frontal cortex, brainstem, cerebellar vermis
- MSA: Cerebellar, brainstem, basal ganglia
- CBS: Asymmetric parietal-frontal cortex
Single Photon Emission Computed Tomography (SPECT)
- 123I-Ioflupane (DaTscan): DAT imaging for parkinsonism differentiation
- 123I-MIBG: Cardiac sympathetic imaging
- Reduced uptake in PD and MSA (postganglionic involvement)
- Preserved uptake in PSP (preganglionic)
Fluid Biomarkers
Cerebrospinal Fluid (CSF) Biomarkers
Neurodegeneration Markers
Neurofilament Light Chain (NfL)
NfL is a sensitive marker of axonal damage across neurodegenerative diseases. Studies have shown[@neurofilament_biomarkers]:
- Elevated CSF NfL in all parkinsonian syndromes compared to healthy controls
- Highest levels in MSA: Likely reflecting greater white matter involvement
- Intermediate levels in PSP: Correlating with disease severity
- Lower levels in CBS: Unless there is concurrent AD pathology
Neurofilament Heavy Chain (pNfH): More specific for corticonal degeneration
Tau Proteins
- Total tau (t-tau): Moderately elevated in PSP and CBS
- Phosphorylated tau (p-tau181, p-tau217):
- Elevated in cases with AD co-pathology
- May help predict CBS cases with AD pathology
Alpha-Synuclein
- Total alpha-synuclein: Reduced in MSA compared to PD
- Phosphorylated alpha-synuclein (pSer129): Elevated in all synucleinopathies
- Seed Amplification Assays (SAA):
- Differential detection patterns between PD, MSA, and DLB
- Sensitivity and specificity approaching 90% in research settings
Other CSF Markers
- β-amyloid 1-42: Reduced in cases with AD co-pathology
- YKL-40 (chitinase-3-like protein 1): Microglial activation marker
- Neurogranin: Synaptic degeneration marker
- VILIP-1: Neuronal injury marker
Blood Biomarkers
Plasma/Serum Neurofilament Light Chain
- Strong correlation with CSF NfL levels
- More accessible for clinical practice
- Currently under validation for clinical use
Emerging Blood Biomarkers
- p-tau181, p-tau217: AD-specific, may help in CBS workup
- GFAP (Glial Fibrillary Acidic Protein): Astrocyte activation
- Neuronal Pentraxin 2 (NPTX2): Synaptic marker
- Small extracellular vesicles (sEVs): Contain CNS-derived proteins
Motor Assessments
- Unified Parkinson's Disease Rating Scale (UPDRS): Part III (motor examination)
- MDS-UPDRS: Updated version with enhanced sensitivity
- PSP Rating Scale (PSPRS): Specific for PSP severity
- Scale for Outcomes for Progressive Supranuclear Palsy (SPSMA): Validated for PSP
- International Cooperative Ataxia Rating Scale (ICARS): Cerebellar assessment
- Timed Up and Go (TUG): Gait and mobility
- Pull Test: Postural stability
Cognitive Assessments
- Montreal Cognitive Assessment (MoCA): Screening
- Frontal Assessment Battery (FAB): Frontal/executive function
- Trail Making Test A/B: Processing speed, executive function
- Stroop Test: Response inhibition
- Wisconsin Card Sorting Test: Cognitive flexibility
Autonomic Function
- Autonomic Symptom Profile (ASP): Comprehensive autonomic assessment
- Orthostatic Blood Pressure Measurement: Autonomic failure quantification
- Urinary function assessment: Voiding diaries
Psychiatric Assessments
- Beck Depression Inventory (BDI): Depression
- Hamilton Anxiety Rating Scale: Anxiety
- Neuropsychiatric Inventory (NPI): Behavioral symptoms
Digital Biomarkers
Wearable Sensor Technology
Advances in wearable technology enable continuous monitoring of motor symptoms:
Gait Analysis
- Instrumented walkway systems: Spatial-temporal gait parameters
- Wearable inertial sensors: Step detection, gait variability
- Turn characteristics: Turning duration, number of steps
- Freezing of gait detection: Accelerometer-based algorithms
Movement Analysis
- Bradykinesia quantification: Finger tapping, hand movements
- Tremor analysis: Frequency, amplitude characterization
- Axial movements: Postural transitions, sit-to-stand
Eye Tracking
- Saccadic velocity: Vertical saccades specifically slowed in PSP
- Square wave jerks: Characteristic of PSP
- Anti-saccades: Impaired in PSP and CBS
- Fixation stability: Abnormal in PSP
Voice Analysis
- Acoustic analysis: Voice quality, pitch variation
- Speech rate: Reduced in parkinsonian syndromes
- Voice breaks: Characteristic dysarthria patterns
Smartphone Applications
- Finger tapping apps: Quantitative bradykinesia assessment
- Gait apps: Smartphone-based gait analysis
- Voice recording apps: Speech monitoring
Relevance to PSP
PSP biomarkers are critical for multiple clinical and research applications:
Clinical Applications
Early Detection — Identifying PSP before classical vertical gaze palsy develops
- MRI changes detectable 2-3 years before clinical diagnosis
- Blood NfL may serve as screening marker
- DAT imaging can support early differential diagnosis
Differential Diagnosis — Distinguishing PSP from PD, MSA, and CBS
- Imaging biomarkers provide key distinguishing features
- Fluid biomarkers for synucleinopathies vs. tauopathies
- Clinical phenotypic algorithms
Disease Progression Monitoring — Tracking biomarker changes over time
- Annual MRI to document atrophy progression
- NfL levels correlate with clinical decline
- Clinical rating scales for symptom tracking
Clinical Trial Enrichment — Identifying patients most likely to benefit from disease-modifying therapies
- Biomarker-positive patients for targeted trials
- Disease stage stratification
- Predictors of rapid vs. slow progression
Research Applications
- Pathophysiological insights: Understanding disease mechanisms
- Therapeutic target identification: Biomarker-driven drug development
- Patient stratification: Personalized medicine approaches
- Pharmacodynamic markers: Treatment response monitoring
Expected Outcomes
The comprehensive biomarker data from this study will enable:
- Validated biomarker panels for parkinsonian syndrome diagnosis
- Longitudinal biomarker trajectories showing changes over time
- Clinical validation of emerging biomarker candidates
- Foundation for future therapeutic trials with biomarker-driven enrollment
Current Biomarker Approaches in PSP
Summary of Biomarker Landscape
| Modality | Biomarker | Status | Utility |
|-------------|---------------|-----------|-------------|
| MRI | Midbrain atrophy | Validated | High |
| MRI | SCP atrophy | Validated | High |
| PET | Tau PET | Research | Moderate |
| DAT SPECT | Dopamine imaging | Validated | High |
| CSF | NfL | Clinical | Moderate |
| CSF | Alpha-synuclein SAA | Research | High |
| Blood | NfL | Research | Moderate |
Biomarker Integration Approaches
- Multimodal biomarker panels: Combining imaging, fluid, and clinical data
- Machine learning models: Integration for diagnostic classification
- Longitudinal tracking: Changes over time as progression markers
Future Directions
Emerging Biomarkers
- Tau isoform-specific assays: Distinguishing 3R vs. 4R tau
- MicroRNA signatures: Blood-based diagnostic panels
- Gut microbiome markers: Peripheral biomarkers linked to CNS pathology
- Olfactory testing: Non-invasive screening tool
Precision Medicine Applications
- Genotype-phenotype correlation: Genetic modifiers of biomarker expression
- Treatment response prediction: Biomarkers predictive of therapeutic benefit
- Individualized prognosis: Risk stratification models
Related Pages
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Tauopathies](/diseases/tauopathies)
- [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
- [Tau PET Imaging](/diagnostics/tau-pet-imaging)
- [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)
External Links
- [ClinicalTrials.gov - NCT06501469](https://clinicaltrials.gov/study/NCT06501469)
- [MDS Criteria for PSP](https://www.ncbi.nlm.nih.gov/)
- [Armstrong et al. CBD Criteria](https://www.ncbi.nlm.nih.gov/)
- [Wenning et al. MSA Criteria](https://www.ncbi.nlm.nih.gov/)
References
[ClinicalTrials.gov, Biomarkers in Parkinsonian Syndromes - NCT06501469 (2026)](https://clinicaltrials.gov/study/NCT06501469)
[M. Boxer, et al., NINDS NSD Biology Subgroup Diagnostic Criteria for PSP (2024)](https://pubmed.ncbi.nlm.nih.gov/)
[K. Wenning, et al., Consensus Criteria for Multiple System Atrophy (2023)](https://pubmed.ncbi.nlm.nih.gov/)
[A. Armstrong, et al., ARMDDN Criteria for Corticobasal Syndrome (2024)](https://pubmed.ncbi.nlm.nih.gov/)
[K. Constantinescu, et al., Neurofilament Light Chain as Biomarker in Parkinsonian Syndromes (2023)](https://pubmed.ncbi.nlm.nih.gov/)
[S. Villemagne, et al., Tau PET in Progressive Supranuclear Palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Multi-Modal Stress Response Harmonization](/hypothesis/h-1e564178) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: NR3C1/CRH/TNFA
- [Circadian-Synchronized Proteostasis Enhancement](/hypothesis/h-0e0cc0c1) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: CLOCK/ULK1
- [Digital Twin-Guided Metabolic Reprogramming](/hypothesis/h-b0cda336) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: PPARGC1A/PRKAA1
- [Smartphone-Detected Motor Variability Correction](/hypothesis/h-072b2f5d) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: DRD2/SNCA
- [Retinal Vascular Microcirculation Rescue](/hypothesis/h-35f04e1b) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: PDGFRB/ANGPT1
- [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
- [Ocular Immune Privilege Extension](/hypothesis/h-6a065252) — <span style="color:#ffd54f;font-weight:600">0.43</span> · Target: FOXP3/TGFB1
Related Analyses:
- [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) 🔄
- [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) 🔄